Month: April 2022

Conference Call and Webcast Scheduled for Thursday, May 5th at 5:00 pm ET RADNOR, Pa., April 25, 2022 (GLOBE NEWSWIRE) — Safeguard Scientifics, Inc. (NYSE:SFE) will release its financial results for the first quarter ended March 31, 2022 after the market close on Thursday, May 5, 2022. CONFERENCE CALL AND WEBCAST DETAILS Please call 10-15 minutes prior to the call to register. Date:   Thursday, May 5, 2022 Time:   5:00 pm ET Live Number:   888-482-7458   Webcast link: https://www.webcast-eqs.com/safeguard05052022_en/en Speakers:   Chief Executive Officer, Eric C. Salzman; and Senior Vice President and Chief Financial Officer, Mark A. Herndon Format:   Discussion of the first quarter of 2022 financial results followed by Q&A The replay will also be available at the webcast link above. For more information please contact IR@safeguard.com.  About...

SALT LAKE CITY, April 25, 2022 (GLOBE NEWSWIRE) — Clarus Corporation (NASDAQ: CLAR) (“Clarus” and/or the “Company”), a global company focused on the outdoor and consumer enthusiast markets, will hold a conference call on Monday, May 9, 2022, at 5:00 p.m. Eastern time to discuss its financial results for the first quarter ended March 31, 2022. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Date: Monday, May 9, 2022Time: 5:00 p.m. Eastern time (3:00 p.m. Mountain time) Toll-free dial-in number: 1-877-511-3707International dial-in number: 1-786-815-8672Conference ID: 3778768 Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty...

–  Met pre-specified efficacy endpoints in chronic pouchitis, a difficult-to-treat inflammatory bowel disease (IBD)–  AMT-101 demonstrated favorable clinical activity and appeared safe and well-tolerated, supporting potentially best-in-class profile–  Achieved clinically meaningful responses in stool frequency and histologic healing in both 3mg and 10mg dosage groups–  Independent Data Monitoring Committee (DMC) recommends advancing to Phase 3 in chronic pouchitis–  Further substantiates potential of AMT-101 and Company’s oral biologics platform–  Investor conference call and webcast today at 8:30 a.m. ET (5:30 a.m. PT) SOUTH SAN FRANCISCO, Calif., April 25, 2022 (GLOBE NEWSWIRE) — Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced positive top-line Phase 2 results from the FILLMORE monotherapy trial for AMT-101...

MONTREAL, April 25, 2022 (GLOBE NEWSWIRE) — Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has filed a provisional patent application in the United States covering the recently communicated mRNA molecules found in pre-clinical trials to be effective at destroying cancer cells grown in culture. The patent application contains composition and utility subject matter pertaining to the structure and sequence of the relevant mRNA molecules. The cytotoxic effects of the subject mRNA molecules were tested on different cancer cells including multidrug resistant breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), and pancreatic cancer cells (SUIT-2). In contrast to cancer...

Hazy Oasis Pale Ale and Featherhammer Ale Available This Week Watertown, NY, April 25, 2022 (GLOBE NEWSWIRE) — 1812 BREWING COMPANY, INC. (OTC Pink: KEGS) (the “Company”) is pleased to announce that on the heels of its flagship War of 1812 Amber Ale earning a top medal in the 2022 New York International Beer Competition, it is releasing two new beers this week.  Available at its Sackets Harbor location will be the new Hazy Oasis Pale Ale and Featherhammer Ale. Hazy Oasis Pale Ale (4.7% ABV) is an American-style hazy pale ale brewed with a variety of hops including Mosaic and Citra and fermented with a special yeast that elevates these hops’ flavors.  When drinking Hazy Oasis you’ll notice tropical aromas of mango, guava, and passion fruit that make it easy to drink.  Featherhammer Ale (8% ABV) is a German style Maibock...

SteelPhalt has introduced the world’s first carbon-negative steel slag aggregate-based asphalt using lignin binder product made from trees. CAMP HILL, Pa., April 25, 2022 (GLOBE NEWSWIRE) — Harsco Corporation (NYSE: HSC), a global market leader providing environmental solutions, announced SteelPhalt, a part of its Harsco Environmental division has launched a carbon-negative asphalt product. SteelPhalt’s asphalt products use 95% recycled steel slag. Prior SteelPhalt asphalt products use bitumen to bind the asphalt. Bitumen is an oil-based binder product with a significant carbon footprint. SteelPhalt’s new asphalt product, called SteelSurf ECO+, uses kraft lignin-based Lineo®, a renewable bio-based substance, supplied by GautamZenUK in collaboration with Stora Enso, as an alternative to bitumen dramatically reducing the product’s...

Results from patient preference questionnaire indicate that people with narcolepsy preferred the once-nightly over the twice-nightly dosing regimen for oxybates Nocturnal adverse event questionnaires characterize the burden associated with the second dose required for twice-nightly oxybatesDUBLIN, Ireland, April 25, 2022 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the presentation of interim data from the ongoing RESTORE open-label extension/switch study of FT218 at the 2022 American Academy of Neurology Annual (AAN) Meeting being held virtually from April 24-26, 2022. FT218 is the Company’s lead drug candidate, an investigational formulation of sodium oxybate designed to be taken once at bedtime for the treatment...

Conference call and webcast to follow at 5:30 p.m. EDT LONG BEACH, NY , April 25, 2022 (GLOBE NEWSWIRE) — authID.ai (Nasdaq: AUID), a leading provider of secure, mobile, biometric identity authentication solutions, today announced it will report financial results for the first quarter ended March 31, 2022 on Monday, May 9, after market close. Following the earnings release, authID.ai Chief Executive Officer Tom Thimot, and Chief Financial Officer Stu Stoller will host a webcast and conference call at 5.30 p.m. EDT to discuss the financial results and provide a corporate update. To listen to the webcast and view the presentation, investors can follow this link: https://edge.media-server.com/mmc/p/3sjqwpia. The slides can also be accessed via authID.ai’s Investor Relations web page at: https://investors.authid.ai/  To participate...

Interim analysis provides response data from 7 evaluable patients including two additional patients, one with non-Hodgkin lymphoma (NHL) and one with acute lymphoblastic leukemia (ALL) Six-month CR rate of 29%, including 1 ongoing CR at 34 weeks in heavily pretreated patients Encouraging response rates at low doses: 57% overall response rate (ORR), 71% disease control rate (DCR) Two responses observed in patients who failed previous autologous CAR-T therapy Allogeneic CD19 CAR-NKT cells well tolerated with 3 cases of grade 1 cytokine release syndrome (CRS), no immune effector cell-associated neurotoxicity syndrome (ICANS) and no graft versus host disease (GvHD) Early responses at low doses suggest promise of “off-the-shelf” cancer immunotherapy platformBUFFALO, N.Y., April 25, 2022 (GLOBE NEWSWIRE) — Athenex, Inc., (NASDAQ:...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 25, 2022 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced publication of a preclinical report on petosemtamab (Peto, MCLA-158: LGR5 x EGFR Biclonics®) in the journal Nature Cancer. The publication will be available at 11:00 a.m. ET today. The report describes the use of the company’s Biclonics® platform to perform a large-scale functional screen of bispecific antibodies resulting in selection of Peto, a bispecific antibody targeting the epidermal growth factor receptor (EGFR) and the leucine-rich repeat containing G protein-coupled receptor (LGR5). Peto displayed potent growth inhibition of colorectal...